APA (7th ed.) Citation

Hall, S. A. L., Burns, G. S., Anagnostou, D., Vogrin, S., Sundararajan, V., Ratnam, D., . . . Littlejohn, M. (2022). Stopping nucleot(s)ide analogues in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels. Alimentary Pharmacology & Therapeutics, 56(2), 310. https://doi.org/10.1111/apt.16968

Chicago Style (17th ed.) Citation

Hall, Samuel A. L., et al. "Stopping Nucleot(s)ide Analogues in Non‐cirrhotic HBeAg‐negative Chronic Hepatitis B Patients: HBsAg Loss at 96 weeks Is Associated with Low Baseline HBsAg Levels." Alimentary Pharmacology & Therapeutics 56, no. 2 (2022): 310. https://doi.org/10.1111/apt.16968.

MLA (9th ed.) Citation

Hall, Samuel A. L., et al. "Stopping Nucleot(s)ide Analogues in Non‐cirrhotic HBeAg‐negative Chronic Hepatitis B Patients: HBsAg Loss at 96 weeks Is Associated with Low Baseline HBsAg Levels." Alimentary Pharmacology & Therapeutics, vol. 56, no. 2, 2022, p. 310, https://doi.org/10.1111/apt.16968.